Authors: | Dejan, J.; Rugo, H. S.; Chia, S. K. L.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Ciruelos, E. M.; Neven, P.; Park, Y. H.; Arce, C. H.; Gu, E.; Joshi, M.; Roux, E.; Akdere, M.; Turner, N. C. |
Abstract Title: | Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study |
Meeting Title: | 2022 ASCO Annual Meeting |
Journal Title: | Journal of Clinical Oncology |
Volume: | 40 |
Issue: | 16 Suppl. |
Meeting Dates: | 2022 Jun 3-7 |
Meeting Location: | Chicago, IL |
ISSN: | 0732-183X |
Publisher: | American Society of Clinical Oncology |
Date Published: | 2022-06-01 |
Language: | English |
ACCESSION: | WOS:000863680300075 |
PROVIDER: | wos |
DOI: | 10.1200/JCO.2022.40.16_suppl.1018 |
Notes: | Meeting Abstract: 1018 -- This meeting was also held virtually -- Source: Wos |